447 related articles for article (PubMed ID: 17451664)
21. Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Blank M; George J; Barak V; Tincani A; Koike T; Shoenfeld Y
J Immunol; 1998 Nov; 161(10):5303-12. PubMed ID: 9820503
[TBL] [Abstract][Full Text] [Related]
22. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity.
Sheng Y; Kandiah DA; Krilis SA
J Immunol; 1998 Aug; 161(4):2038-43. PubMed ID: 9712077
[TBL] [Abstract][Full Text] [Related]
23. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
Chehadeh W; Halim MA; Al-Nakib W
Virology; 2009 Jul; 390(1):56-63. PubMed ID: 19450862
[TBL] [Abstract][Full Text] [Related]
24. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
25. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins.
Bertolaccini ML; Hughes GR; Khamashta MA
Clin Lab; 2004; 50(11-12):653-65. PubMed ID: 15575307
[TBL] [Abstract][Full Text] [Related]
26. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
27. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution.
Tincani A; Spatola L; Prati E; Allegri F; Ferremi P; Cattaneo R; Meroni P; Balestrieri G
J Immunol; 1996 Dec; 157(12):5732-8. PubMed ID: 8955227
[TBL] [Abstract][Full Text] [Related]
28. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.
Ros C; Gerber M; Kempf C
J Virol; 2006 Dec; 80(24):12017-24. PubMed ID: 17020940
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
30. Human parvovirus B19 infection and autoimmunity.
Lunardi C; Tinazzi E; Bason C; Dolcino M; Corrocher R; Puccetti A
Autoimmun Rev; 2008 Dec; 8(2):116-20. PubMed ID: 18700174
[TBL] [Abstract][Full Text] [Related]
31. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties.
Lunardi C; Tiso M; Borgato L; Nanni L; Millo R; De Sandre G; Severi AB; Puccetti A
Eur J Immunol; 1998 Mar; 28(3):936-48. PubMed ID: 9541589
[TBL] [Abstract][Full Text] [Related]
32. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
33. β2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3β expression and reduces experimental-antiphospholipid-syndrome.
Blank M; Baraam L; Eisenstein M; Fridkin M; Dardik R; Heldman Y; Katchalski-Katzir E; Shoenfeld Y
J Autoimmun; 2011 Aug; 37(1):8-17. PubMed ID: 21524885
[TBL] [Abstract][Full Text] [Related]
34. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
Heegaard ED; Rasksen CJ; Christensen J
J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
[TBL] [Abstract][Full Text] [Related]
35. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Blank M; Faden D; Tincani A; Kopolovic J; Goldberg I; Gilburd B; Allegri F; Balestrieri G; Valesini G; Shoenfeld Y
J Autoimmun; 1994 Aug; 7(4):441-55. PubMed ID: 7980847
[TBL] [Abstract][Full Text] [Related]
36. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
37. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
[TBL] [Abstract][Full Text] [Related]
38. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis.
Matsuura E; Kobayashi K; Tabuchi M; Lopez LR
Prog Lipid Res; 2006 Nov; 45(6):466-86. PubMed ID: 16790279
[TBL] [Abstract][Full Text] [Related]
39. The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome.
Yodfat O; Blank M; Krause I; Shoenfeld Y
Clin Immunol Immunopathol; 1996 Jan; 78(1):14-20. PubMed ID: 8599879
[TBL] [Abstract][Full Text] [Related]
40. The VP1-unique region of parvovirus B19 induces myocardial injury in mice.
Nie X; Zhang G; Xu D; Sun X; Li Z; Li X; Zhang X; He F; Li Y
Scand J Infect Dis; 2010; 42(2):121-8. PubMed ID: 19883162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
